Caprine and ovine brucellosis, caused by the zoonotic bacterium Brucella melitensis, is an economically important cause of abortion in small ruminants. This infection causes significant losses from decreased productivity and lost trade in much of the developing world. B. melitensis is considered to be a re-emerging pathogen in the Middle East.
GALVmed (www/galvmed.org) has been asked to be involved in a Brucellosis vaccine pilot project for the development of an improved, safe, low-cost & efficacious vaccine for Brucella melitensis. The project will involve a significant prize for the company that manages to develop and register a safe and efficacious brucellosis vaccine in the EU, as well as two attractive milestone payments for the successful participants as they move along the vaccine development process.
This innovation initiative (funded by several well-respected international development agencies and modelled on similar successful approaches in other areas of agriculture) will establish and manage a brucellosis vaccine pilot project with the objective of developing an improved, safe, low-cost and efficacious vaccine for Brucella melitensis registered for field use. This project works by incentivising “solver” organisations through stage-gate driven “prizes”, with a very significant final prize for the successful solver. The project is expected to be funded for approximately 9 years, with an initial fully-funded 2 ½ year pilot phase.
The Project Manager will oversee the development of vaccines in partner organisations and be responsible for all aspects of the project under a relatively high level of external scrutiny. This exciting opportunity comes with a competitive salary.
For a full job description and details of how to apply, click here.